Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
Why Is Beta Bionics (BBNX) Stock Down -12.34% Today?

Why Is Beta Bionics (BBNX) Stock Down -12.34% Today?

Key Takeaways

  • BBNX shares fell roughly 12.3% on Wednesday, October 28, 2026, sliding from a prior close of $21.39 to about $18.75.
  • The primary catalyst was the company's third-quarter 2026 earnings report, which revealed a widening net loss and an FDA request to withdraw and resubmit the 510(k) filing for its 3D Intelligence algorithm.
  • A secondary driver was softer implied fourth-quarter revenue guidance of $29–31 million, a sequential decline from Q3's record $35.5 million.
  • The decline reflects a combination of a regulatory setback, margin pressure, and profit-taking following a strong multi-week run in the shares.
  • Traders are now watching the company's Mint patch pump commercial launch timeline, the 3D Intelligence resubmission, and fourth-quarter execution.
  • For deeper analysis of Price Targets, Earnings, and Forecast data, explore Tickeron's dedicated pages for BBNX.
  • To see which automated strategies are currently leading the market, visit the Trending AI Robots page.

Opening Summary

Beta Bionics, Inc. (BBNX), a commercial-stage medical device company best known for its iLet Bionic Pancreas automated insulin delivery system, tumbled on Wednesday, October 28, 2026. Shares dropped approximately 12.3% to around $18.75, down from the prior session's closing price of $21.39. The move lower followed the company's third-quarter 2026 earnings release, reported after Tuesday's close, which beat on revenue but was overshadowed by a wider net loss, a regulatory delay for its next-generation dosing algorithm, and fourth-quarter guidance implying a sequential slowdown in sales.

FDA Setback for 3D Intelligence Algorithm

The most significant headline pressuring BBNX was a regulatory development tied to its innovation pipeline. During the earnings call, management disclosed that the company had withdrawn its 510(k) submission for 3D Intelligence—the next-generation insulin-dosing algorithm unveiled in September—at the request of the U.S. Food and Drug Administration. After a 90-day review period, the agency asked for additional validation work, prompting a withdrawal and resubmission that management said is planned for mid-fourth quarter 2026.

While executives framed the issue as a technical question around simulation validation rather than a problem with the algorithm itself, the delay nonetheless pushes the expected U.S. launch of iLet 3D and Mint 3D to around mid-2027. For a company whose growth narrative rests heavily on an expanding product platform, the setback raised near-term uncertainty and prompted investors to reassess the timeline of future catalysts.

Widening Losses and Margin Pressure

The earnings report itself delivered mixed signals. BBNX posted record third-quarter net sales of $35.5 million, up about 30% year over year and ahead of consensus estimates, driven by growth in new patient starts and the expanding pharmacy-channel installed base. However, profitability deteriorated. The company reported a net loss of $24.4 million, compared with a $14.2 million loss in the prior-year quarter, while operating expenses climbed 46% year over year to $46.9 million.

Gross margin also slipped sequentially to 57.3%, down from 59% in the second quarter, reflecting an unfavorable mix tied to distributor stocking dynamics in higher-margin DME iLet sales. Although management attributed the decline to temporary inventory variability rather than weaker demand, the combination of rising costs and margin compression weighed on sentiment.

Softer Fourth-Quarter Revenue Outlook

Guidance added to the downward pressure. BBNX narrowed its full-year 2026 revenue range to approximately $124–126 million, raising the lower end from $121 million. But the implied fourth-quarter outlook of $29–31 million represents a sequential decline from the third quarter's $35.5 million, partly reflecting an anticipated revenue deferral of up to $8.5 million as prospective iLet users wait for the upcoming Mint patch pump launch. The prospect of a near-term top-line pullback, even if expected to be recovered in 2027, reinforced the bearish tone in Wednesday's trading.

Market Context and Trading Activity

The sell-off came on active trading volume as investors absorbed the post-earnings details, extending a decline that began in after-hours trading on Tuesday. The drop also unwound part of a sharp recent rally—BBNX had gained more than 20% over the prior five sessions—leaving the stock vulnerable to profit-taking once the regulatory and guidance details emerged. The move reflected company-specific news rather than broad sector weakness, with the shares trading well below their 52-week high of $32.71 reached in late 2025 and above their April 2026 low of $8.80.

What Comes Next for BBNX

Looking ahead, investors will focus on several catalysts. The full U.S. commercial launch of the FDA-cleared Mint patch pump is expected in the first quarter of 2027, and the company has signaled 2027 revenue of roughly $190 million or higher. Nearer term, attention turns to the resubmitted 510(k) for 3D Intelligence and the initiation of a pivotal trial for a fully closed-loop algorithm that would remove meal announcements. Risks remain, including ongoing operating losses, execution around the Mint manufacturing ramp, and the timing of regulatory clearances for its pipeline programs.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies that are currently performing strongly. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under prevailing market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to evaluate. Explore the Trending AI Robots to see which automated strategies are leading the market today.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BBNX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


BBNX's Stochastic Oscillator is remaining in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +9.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBNX advanced for three days, in 81 of 97 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

BBNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for BBNX moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 20 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BBNX as a result. In 18 of 25 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.

The Moving Average Convergence Divergence Histogram (MACD) for BBNX turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 12 similar instances when the indicator turned negative. In 11 of the 12 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

BBNX moved below its 50-day moving average on October 28, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for BBNX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.304) is normal, around the industry mean (4.142). P/E Ratio (-9.812) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (8.251) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. BBNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
11 Hughes
Phone
+1 949 427-7785
Employees
423
Web
https://www.betabionics.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.